secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0001104659-23-117678
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount
--------------------------------------------------------------------------------

- Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.
- Strategic realignment reduces headcount ~30%, targets cutting total resource consumption by half.
- Cash, equivalents, and short-term deposits at $1.4M as of Sep 30, 2023, down from $3M at Dec 31, 2022.
- Net loss for Q3 2023 was $1.2M ($0.03 per share) vs. $6.9M ($0.19 per share) in Q3 2022.
- Raised ~$7.5M gross in July 2023 registered direct offering with a single institutional investor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/0001104659-23-117678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/tm2330690d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer